Polypeptide With Localisation/Targeting Motif TRIZ Cases

Modified SacB signal sequences improve heterologous protein secretion efficiency and yield in Bacillus licheniformis by resolving translation bottlenecks.

Biotinylated envelope tags enable streptavidin capture, resolving low recovery and laborious ultracentrifugation bottlenecks.

Specific artificial antigenic epitope activation maintains central memory T cell proportions during culture, resolving productivity versus stability trade-offs.

Removing human-mimicking epitopes from the Zika NS1 protein prevents autoimmune responses while preserving protective immunity against flaviviruses.

Optimized TCR variable regions bind HPV 16 E6 and E7 oncoproteins, addressing inadequate therapeutic effectiveness against cancer progression.

Engineered small Type II-D Cas proteins form complexes with guide RNAs to enable precise sequence-specific binding of target nucleic acids.

Chimeric antigen receptors employ CD4 and LAT intracellular motifs to recruit Lck and PLCγ, enabling tumor targeting without fratricide.

A recombinant vector incorporates a BiP fragment to link target proteins and enhance expression levels.

Immunoresponsive cells express two chimeric antigen receptors with distinct co-stimulatory domains to recognize diverse tumor antigens.

Specific amino acid sequences in conjugation handles modulate antibody-drug conjugate stability, preventing premature payload release in plasma.

Monoclonal antibodies bind denatured human CD70 in fixed tissue samples to enable precise cancer diagnosis.

Unimolecular FRET probe detects autophagy by using enzymatic degradation of an acceptor protein, resolving lysosomal pH interference.

Segmented and extracted transmembrane regions enable large-scale production of stable tetrameric neuraminidase without heterologous domains.

An antibody fusion protein links a variable region to an NKG2D ligand domain.

Liposomes display antigenic polypeptides on surfaces modified with polyethylene glycol chains to stimulate immune responses.

Modified Fc domains act as intermediaries between tumor antibodies and T cells, reducing off-target toxicity while maintaining effective lysis.

Modified gene therapy vector uses a secretory leader sequence to release therapeutic proteins from transduced cells.

DNA plasmids co-express targeting polypeptides with immunoinhibitory compounds to induce antigen-specific tolerance.

Allogeneic iPSC-derived CAR-T cells target CD19 and CD22 to resolve production bottlenecks while reducing adverse events.

Sortase enzymes attach antigen binding domains to chimeric antigen receptors, preventing degradation and extending T-cell activity.

Peptides translocate into sperm flagella to modulate phosphoprotein phosphatase 1 complexes, enabling reversible contraception without hormonal side effects.

Conjugating neurotensin variants to therapeutic proteins enables precise cellular uptake via sortilin receptor binding.

Stapled bifunctional peptides overcome protease degradation by locking conformation, enabling targeted protein ubiquitination.

A fusion protein combines an E7 peptide with a translocating segment to facilitate cytoplasmic entry and immune activation.

Engineered T cell receptors target mutated RAS proteins to activate immune responses against cancer cells.

Genome-engineered iPSCs provide uniform CAR-T cells, resolving manufacturing heterogeneity from primary cell sourcing.

Chimeric heterocyclic polyamide compounds recruit regulatory molecules to correct fmr1 and fmr2 defects in fragile X syndromes.

Genetically modified CAR T cells express chimeric antigen receptors targeting CD83 to eliminate autoreactive lymphocytes.

A chimeric receptor protein combines human and non-human domains to enhance IgE detection sensitivity in allergy diagnostics.

Segmented nanobodies penetrate tumors and block PD-1/PD-L1 interactions more effectively than monoclonal antibodies.

A chimeric peptide coating anchors to titanium surfaces via a dedicated binding domain while deploying an antimicrobial segment to eliminate bacteria.

Targeted amino acid mutations lower heparin binding affinity, enabling broader neurturin distribution in the brain while retaining neurotrophic activity.

Specific amino acid substitutions in PD-L1 variants enhance PD-1 binding affinity while reducing immunogenicity risks.

Segmented liver and blood stage antigens with IL-12 adjuvants overcome partial protection limits.

Incorporating a human transferrin epitope into chimeric antigen receptors reduces cytokine secretion while maintaining cytotoxic activity against tumor cells.

Anti-TEM1 antibodies target tumor endothelial marker 1, addressing the lack of effective targeting in current cancer therapies.

Peptide-based complexes anchor transferred cells to cardiac tissue, solving low retention rates without genetic modification.

Apoptotic cell supernatant reduces IL-6 production to control cytokine release syndrome while maintaining anti-tumor efficacy.

Improved modular antigen transportation molecules substitute cysteine residues with serine, leucine, or isoleucine to enhance solubility and stability.

Specific PhoS mutations alter phosphorylation states to increase secreted protein accumulation, resolving efficiency limits in bacterial production systems.

Fragment peptides mobilize mesenchymal stem cells into peripheral blood, avoiding invasive bone marrow aspiration and in vitro culture limitations.

Engineered T cells present viral antigens to boost engraftment while reducing cell attrition.

A synthetic transcription factor activates an mRNA anti-sense repressor switch to silence target transcripts in mammalian cells.

Nanoligomers target NLRP3 and NF-kB pathways to reduce glial inflammation while crossing the blood-brain barrier.

Antisense transfer vector enables independent gene expression in lentiviral vectors.

Conjugating a nuclear localization signal to guide RNA protects the molecule from nuclease degradation and directs it to the nucleus.

Modified Cpf1 nucleases enable precise genomic DNA editing across broad temperature ranges.